Obesity Therapy
Polymorphisms in SLC6A2 and GRIN1 affect weight loss response of GW320659 in obese subjects
Published in Obesity and Diabetes Week, January 23rd, 2006
"GW320659, a highly selective neuronal norepinephrine and dopamine reuptake inhibitor, has been evaluated for the treatment of obesity. Scrutiny of the weight loss data from a phase II study (GlaxoSmithKline study OBS20001) showed a wide variation in weight loss response following GW320659 treatment and the possibility that the study population might include subgroups with enhanced weight loss response," scientists in England report.
C.F. Spraggs and colleagues at GlaxoSmithKline explained,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Epidemiology
Two major quantitative trait loci and others relate to factors of metabolic syndrome - Diet & Nutrition
Maternal preoccupation with weight was linked to restrained eating behavior in offspring - Obesity Complications
Investigation found no influence of BMI on early total hip arthroplasty outcome - Obesity Pathogenesis
Leptin potentiates ADP-induced [Ca2+]i increase via JAK2 and tyrosine kinases - Obesity Therapy
Increased adiponectin levels may be effective in reducing insulin resistance in obese - Adolescent Health
Researchers identify factors associated with excess weight in teens - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
